Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABP Abpro	$0.26 +1.5%	$0.24	$0.15 ▼ $13.00	$19.65M	0.03	5.91 million shs	1.10 million shs
CYCC Cyclacel Pharmaceuticals	$7.68 -0.1%	$8.23	$3.08 ▼ $597.60	$18.44M	0.15	190,470 shs	61,894 shs
IPCIF Intellipharmaceutics International		$0.00	$0.00 ▼ $0.15	$4.96M	1.53	12,042 shs	323,750 shs
IXHL Incannex Healthcare	$0.62 -2.2%	$0.51	$0.08 ▼ $3.12	$19.40M	7.66	134.11 million shs	31.21 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABP Abpro	+1.55%	+4.49%	+7.07%	+20.58%	+25,599,900.00%
CYCC Cyclacel Pharmaceuticals	-0.13%	-4.83%	-21.71%	-15.37%	-97.04%
IPCIF Intellipharmaceutics International	0.00%	0.00%	0.00%	0.00%	0.00%
IXHL Incannex Healthcare	-2.19%	-6.91%	+40.32%	+248.60%	-63.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABP Abpro	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	1.4545 of 5 stars	0.0	5.0	0.0	0.0	2.5	2.5	0.0
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	0.5448 of 5 stars	0.0	4.0	0.0	0.0	1.8	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABP Abpro	3.00	Buy	$4.00	1,462.50% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
IPCIF Intellipharmaceutics International	0.00	N/A	N/A	N/A
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABP Abpro	$180K	114.02	N/A	N/A	($0.21) per share	-1.22
CYCC Cyclacel Pharmaceuticals	$40K	430.08	N/A	N/A	$1.62 per share	4.74
IPCIF Intellipharmaceutics International	$660K	0.00	N/A	N/A	($0.32) per share	0.00
IXHL Incannex Healthcare	$10K	1,836.43	N/A	N/A	$0.18 per share	3.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABP Abpro	-$7.23M	N/A	0.00	∞	N/A	N/A	N/A	-241.16%	N/A
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-723.64%	-145.51%	11/10/2025 (Estimated)
IPCIF Intellipharmaceutics International	-$2.89M	-$0.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)

Latest IPCIF, ABP, IXHL, and CYCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2025	Q4 2025	IXHL Incannex Healthcare	-$0.29	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ABP Abpro	N/A	-$0.04	N/A	-$0.05	N/A	N/A
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABP Abpro	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABP Abpro	N/A	0.15	0.15
CYCC Cyclacel Pharmaceuticals	N/A	5.77	5.77
IPCIF Intellipharmaceutics International	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABP Abpro	23.30%
CYCC Cyclacel Pharmaceuticals	23.58%
IPCIF Intellipharmaceutics International	N/A
IXHL Incannex Healthcare	0.43%

Insider Ownership

Company	Insider Ownership
ABP Abpro	20.80%
CYCC Cyclacel Pharmaceuticals	51.20%
IPCIF Intellipharmaceutics International	1.76%
IXHL Incannex Healthcare	15.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABP Abpro	15	80.17 million	63.49 million	N/A
CYCC Cyclacel Pharmaceuticals	14	2.24 million	1.09 million	Optionable
IPCIF Intellipharmaceutics International	10	33.09 million	32.51 million	Not Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable

IPCIF, ABP, IXHL, and CYCC Headlines

Recent News About These Companies

Best Cannabis Stocks To Add to Your Watchlist - August 29th

September 1 at 4:21 AM | americanbankingnews.com

Cannabis Stocks To Keep An Eye On - August 25th

August 28, 2025 | americanbankingnews.com

Cannabis Stocks To Watch Today - August 26th

August 28, 2025 | americanbankingnews.com

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

August 26, 2025 | globenewswire.com

Top Cannabis Stocks To Keep An Eye On - August 23rd

August 26, 2025 | americanbankingnews.com

Promising Cannabis Stocks To Follow Now - August 24th

August 26, 2025 | americanbankingnews.com

Best Cannabis Stocks To Consider - August 22nd

August 25, 2025 | americanbankingnews.com

Top Cannabis Stocks To Follow Now - August 21st

August 24, 2025 | americanbankingnews.com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

August 22, 2025 | msn.com

Incannex Healthcare Inc. Launches $20 Million Share Repurchase Program to Enhance Shareholder Value

August 22, 2025 | quiverquant.comQ

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

August 22, 2025 | globenewswire.com

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

August 19, 2025 | newsfilecorp.comN

Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

August 17, 2025 | msn.com

Incannex Healthcare: Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

August 9, 2025 | finanznachrichten.de

Incannex Shares Surge Following Promising Sleep Apnea Trial Data

August 8, 2025 | msn.com

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

August 8, 2025 | globenewswire.com

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

July 31, 2025 | globenewswire.com

Incannex reports results from RePOSA Phase 2 trial of IHL-42X

July 30, 2025 | msn.com

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

July 30, 2025 | globenewswire.com

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

July 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, ABP, IXHL, and CYCC Company Descriptions

Abpro NASDAQ:ABP

$0.26 +0.00 (+1.55%)

As of 09/3/2025 04:00 PM Eastern

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$7.68 -0.01 (-0.13%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$7.70 +0.02 (+0.26%)

As of 05:07 AM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Incannex Healthcare NASDAQ:IXHL

$0.62 -0.01 (-2.19%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$0.60 -0.03 (-4.49%)

As of 05:15 AM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time